FOLH1 and Pancytopenia: to May 2020, last cycle with reduced dose due to pancytopenia); however, 68Ga-PSMA PET/CT (Figure 1E) showed significant progression of the disease in May in 2020 with extensive, intense PSMA-positive inguinal, iliac, retroperitoneal, and mediastinal (infracarinal and retroesophageal) lymph node metastases, mesenteric and peritoneal involvement and infiltration of the pararectal and sigmoidal adipose tissue, intramural bladder wall infiltration as well as bone metastases.